209 related articles for article (PubMed ID: 22359871)
1. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Nikitin AV
Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
[No Abstract] [Full Text] [Related]
2. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
[No Abstract] [Full Text] [Related]
4. Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA
Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline (Teflaro): a new cephalosporin.
Belavic JM
Nurse Pract; 2011 Nov; 36(11):12-3. PubMed ID: 22008594
[No Abstract] [Full Text] [Related]
6. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
8. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
14. Ceftaroline: a comprehensive update.
Kaushik D; Rathi S; Jain A
Int J Antimicrob Agents; 2011 May; 37(5):389-95. PubMed ID: 21420284
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
El Hajj MS; Turgeon RD; Wilby KJ
Int J Clin Pharm; 2017 Feb; 39(1):26-32. PubMed ID: 28058593
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Blumer JL; Ghonghadze T; Cannavino C; O'Neal T; Jandourek A; Friedland HD; Bradley JS
Pediatr Infect Dis J; 2016 Jul; 35(7):760-6. PubMed ID: 27078119
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
19. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Garrison MW; Kawamura NM; Wen MM
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
